Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Out-of-pocket and capitalized costs per approved drug for NMEs only

From: Estimating the clinical cost of drug development for orphan versus non-orphan drugs

Drug Type Phase Expected out-of-pocket clinical costs (in millions 2013 USD) Out-of-pocket clinical cost per approved drug (in millions 2013 USD) Capitalized expected clinical costs (in millions 2013 USD) Capitalized clinical cost per approved drug (in millions 2013 USD)
Non-orphan 1 $2.81 $340.30 $5.16 $488.88
2 $7.00 $11.11
3 $25.75 $34.82
Total $35.56 $51.09
Orphan 1 $4.27 $137.12 $9.61 $242.46
2 $20.86 $39.87
3 $20.02 $30.35
Total $45.15 $79.83
  1. NME = New Molecular Entity